Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage
biopharmaceutical company developing targeted protein modulation
drugs designed to treat patients with hematologic malignancies and
solid tumors, today announced that clinical data will be presented
for its two BTK degrader programs, NX-5948 and NX-2127, in two
posters at the 65th American Society of Hematology Annual Meeting
and Exposition being held December 9-12, 2023, in San Diego, CA.
Nurix will also present a trials in progress poster for its NX-1607
program.
Poster Presentation Details:
Title: Initial findings from first-in-human
phase 1a/b study of NX-5948, a selective Bruton’s tyrosine kinase
(BTK) degrader, in patients with relapsed/refractory B cell
malignanciesAuthors: Emma Searle, Francesco
Forconi, Kim Linton, Alexey Danilov, Pam McKay, David Lewis, Dima
El-Sharkawi, Mary Gleeson, John Riches, Sarah G. Injac, Ted Shih,
Srinand Nandakumar, May Tan, Ganesh Cherala, Erin Meredith, Graham
P. Collinsa Session Name: 626. Aggressive
Lymphomas Prospective Therapeutic Trials: Poster
III Session Date and Time: Monday, December 11,
2023, 6:00 PM - 8:00 PM PT Publication Number:
4473
Title: A first-in-human phase 1 trial of
NX-2127, a first-in-class Bruton's Tyrosine Kinase (BTK)
dual-targeted protein degrader with immunomodulatory activity, in
patients with relapsed/refractory B cell malignancies
Authors: Alexey Danilov, Michael Tees, Krish
Patel, William Wierda, Manish R. Patel, Ian Flinn, Tahir Latif,
Weiyun Ai, Meghan C. Thompson, Michael Wang, Clare Sun, Deborah M.
Stephens, Michael Thirman, Melissa Gessner, Johannes Wolff, Amanda
Schwab, May Tan, Daniel Chan, Erin Meredith, Adrian
Wiestner Session Name: 626. Aggressive
Lymphomas Prospective Therapeutic Trials: Poster
III Session Date and Time: Monday, December 11,
2023, 6:00 PM - 8:00 PM PT Publication Number:
4463
Title: A First-in-Human Phase 1 Trial of
NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with
Advanced Malignancies Including DLBCLAuthors:
Graham P. Collins, William Townsend, Ahmed Abdulgawad, Swathi
Namburi, Anja Williams, Ana Filipa Palma Dos Reis, Matthew G.
Krebs, Jeff Evans, Sarah P. Blagden, Ruth Plummer, Daniel
Hochhauser, Adam Sharp, George Cole, Seema Rogers, Daniel Chan,
Sarah Whelan, Dima El-Sharkawi Session Name:
626. Aggressive Lymphomas Prospective Therapeutic
Trials: Poster III Session Date and Time:
Sunday, December 10, 2023, 6:00 PM - 8:00 PM PT Publication
Number: 3093
About NX-2127 NX-2127 is a novel
bifunctional molecule that degrades BTK and cereblon neosubstrates
Ikaros (IKZF1) and Aiolos (IKZF3). NX-2127 is currently being
evaluated in a Phase 1 clinical trial in patients with relapsed or
refractory B cell malignancies. Additional information on the
ongoing clinical trial can be accessed at www.clinicaltrials.gov
(NCT04830137).
About NX-5948 NX-5948 is an
investigational, orally bioavailable, small molecule degrader of
BTK that, unlike NX-2127, has been designed to lack cereblon
immunomodulatory activity. NX-5948 is currently being evaluated in
a Phase 1 clinical trial in patients with relapsed or refractory B
cell malignancies. Additional information on the ongoing clinical
trial can be accessed at clinicaltrials.gov
(NCT05131022).
About NX-1607 NX-1607 is an orally bioavailable
inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B)
for immuno-oncology indications including a range of solid tumor
types. NX-1607 acts on T cells, NK cells, and dendritic cells to
enhance anti-tumor immunity, and has demonstrated single-agent
anti-tumor activity in multiple tumor models. NX-1607 is currently
being evaluated in a Phase 1 clinical trial in adults with a
variety of oncology indications. Additional information on the
ongoing clinical trial can be accessed at www.clinicaltrials.gov
(NCT05107674).
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company
focused on the discovery, development and commercialization of
medicines based on the modulation of cellular protein levels as a
novel treatment approach for cancer and other challenging diseases.
Leveraging extensive expertise in E3 ligases together with
proprietary DNA-encoded libraries, Nurix has built DELigase, an
integrated discovery platform, to identify and advance novel drug
candidates targeting E3 ligases, a broad class of enzymes that can
modulate proteins within the cell. Nurix’s drug discovery approach
is to either harness or inhibit the natural function of E3 ligases
within the ubiquitin-proteasome system to selectively decrease or
increase cellular protein levels. Nurix’s wholly owned, clinical
stage pipeline includes targeted protein degraders of Bruton’s
tyrosine kinase, a B-cell signaling protein, and inhibitors of
Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that
regulates activation of multiple immune cell types including T cell
and NK cells. Nurix is headquartered in San Francisco, California.
For additional information visit http://www.nurixtx.com.
Forward-Looking Statements
This press release contains statements that relate to future
events and expectations and as such constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. When or if used in this press release, the
words “anticipate,” “believe,” “could,” “estimate,” “expect,”
“intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,”
and similar expressions and their variants, as they relate to
Nurix, may identify forward-looking statements. All statements that
reflect Nurix’s expectations, assumptions or projections about the
future, other than statements of historical fact, are
forward-looking statements, including, without limitation,
statements regarding Nurix’s current and prospective drug
candidates; the planned timing and conduct of the clinical trial
programs for Nurix’s drug candidates; the planned timing for the
provision of updates and findings from Nurix’s clinical studies;
the potential advantages of Nurix’s DELigase™ platform and drug
candidates; and the extent to which Nurix’s scientific approach and
DELigase™ platform may potentially address a broad range of
diseases. Forward-looking statements reflect Nurix’s current
beliefs, expectations, and assumptions regarding the future of
Nurix’s business, its future plans and strategies, its development
plans, its preclinical and clinical results, future conditions and
other factors Nurix believes are appropriate in the circumstances.
Although Nurix believes the expectations and assumptions reflected
in such forward-looking statements are reasonable, Nurix can give
no assurance that they will prove to be correct. Forward-looking
statements are not guarantees of future performance and are subject
to risks, uncertainties and changes in circumstances that are
difficult to predict, which could cause Nurix’s actual activities
and results to differ materially from those expressed in any
forward-looking statement. Such risks and uncertainties include,
but are not limited to: (i) risks and uncertainties related to
Nurix’s ability to advance its drug candidates, obtain regulatory
approval of and ultimately commercialize its drug candidates; (ii)
the timing and results of preclinical studies and clinical trials;
(iii) Nurix’s ability to fund development activities and achieve
development goals; (iv) the timing and receipt of payments from
Nurix’s collaboration partners, including milestone payments and
royalties on future potential product sales; (v) the impact of
macroeconomic conditions, including inflation, increasing interest
rates, volatile market conditions, instability in the global
banking system, uncertainty with respect to the federal budget and
debt ceiling, and global events, including regional conflicts
around the world, on Nurix’s business, clinical trials, financial
condition, liquidity and results of operations; (vi) Nurix’s
ability to protect intellectual property and (vii) other risks and
uncertainties described under the heading “Risk Factors” in Nurix’s
Quarterly Report on Form 10-Q for the fiscal quarter ended August
31, 2023, and other SEC filings. Accordingly, readers are cautioned
not to place undue reliance on these forward-looking statements.
The statements in this press release speak only as of the date of
this press release, even if subsequently made available by Nurix on
its website or otherwise. Nurix disclaims any intention or
obligation to update publicly any forward-looking statements,
whether in response to new information, future events, or
otherwise, except as required by applicable law.
Contacts:
InvestorsSilinda NeouNurix
Therapeuticsir@nurixtx.com
Elizabeth Wolffe, Ph.D.Wheelhouse Life Science
Advisorslwolffe@wheelhouselsa.com
MediaAljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From Apr 2024 to May 2024
Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From May 2023 to May 2024